Publications by authors named "Sathiyavelu Sekar"
Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
Narendran Gopalan Ramesh Kumar Santhanakrishnan Alangudi Natarajan Palaniappan Pradeep Aravindan Menon Sekar Lakshman Padmapriyadarsini Chandrasekaran Chandrasekar Chockalingam Sekar Sathiyavelu
JAMA Intern Med
April 2018
Importance: The benefit of daily over thrice-weekly antituberculosis therapy among HIV-positive patients with pulmonary tuberculosis (TB) who are receiving antiretroviral therapy remains unproven.
Objective: To compare the efficacy and safety of daily, part-daily, and intermittent antituberculosis therapy regimens in the treatment of HIV-associated pulmonary TB.
Design, Setting, And Participants: This open-label, randomized clinical trial was conducted by the National Institute for Research in Tuberculosis, south India.
Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction.
Gopalan Narendran Bruno B Andrade Brian O Porter Chockalingam Chandrasekhar Perumal Venkatesan Sathiyavelu Sekar Chandrasekaran Padmapriyadarshini Lakshmanan Sekar
PLoS One
December 2013
Article Synopsis
- The study investigated the incidence and clinical predictors of paradoxical TB-IRIS in HIV-positive patients with confirmed pulmonary tuberculosis in India, which had not been done prospectively before.
- Patients on anti-tuberculosis therapy were monitored after starting antiretroviral therapy, revealing that over half experienced IRIS events, often requiring corticosteroids for treatment.
- Key predictors for IRIS included lower CD4(+) T-cell counts and higher baseline levels of IL-6 and CRP, suggesting these markers could help forecast IRIS occurrences.